Jazz Pharmaceuticals (JAZZ) is down 2.1% premarket, adding to the losses seen yesterday due to an FDA warning letter related to its Xyrem drug. However, Jefferies and Piper have come to Jazz's defense, with each noting that the warning merely involves the company's monitoring procedures, rather than any production issues.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Investor's Business Daily (Thu, 11:51AM)
at Zacks.com (Wed, 9:30AM)
at Benzinga.com (Tue, 8:37PM)
at Investor's Business Daily (Tue, 7:07PM)
at Benzinga.com (Fri, 8:38AM)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs